ES2856960T3 - Ambrisentan para uso en el tratamiento de insuficiencia renal aguda - Google Patents
Ambrisentan para uso en el tratamiento de insuficiencia renal aguda Download PDFInfo
- Publication number
- ES2856960T3 ES2856960T3 ES17711211T ES17711211T ES2856960T3 ES 2856960 T3 ES2856960 T3 ES 2856960T3 ES 17711211 T ES17711211 T ES 17711211T ES 17711211 T ES17711211 T ES 17711211T ES 2856960 T3 ES2856960 T3 ES 2856960T3
- Authority
- ES
- Spain
- Prior art keywords
- ambrisentan
- administered
- subject
- kidney
- liquid composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310221P | 2016-03-18 | 2016-03-18 | |
| EP16166046.9A EP3235496A1 (en) | 2016-04-19 | 2016-04-19 | Treatment of acute renal failure |
| US201662437949P | 2016-12-22 | 2016-12-22 | |
| PCT/EP2017/056476 WO2017158199A1 (en) | 2016-03-18 | 2017-03-20 | Ambrisentan for use in the treatment of acute renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2856960T3 true ES2856960T3 (es) | 2021-09-28 |
Family
ID=55808404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17711211T Active ES2856960T3 (es) | 2016-03-18 | 2017-03-20 | Ambrisentan para uso en el tratamiento de insuficiencia renal aguda |
| ES20175547T Active ES2966638T3 (es) | 2016-03-18 | 2017-03-20 | Ambrisentan para su uso en el tratamiento de insuficiencia renal aguda |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20175547T Active ES2966638T3 (es) | 2016-03-18 | 2017-03-20 | Ambrisentan para su uso en el tratamiento de insuficiencia renal aguda |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10870021B2 (enExample) |
| EP (3) | EP3235496A1 (enExample) |
| JP (1) | JP7237362B2 (enExample) |
| KR (1) | KR20180121539A (enExample) |
| CN (1) | CN109069443A (enExample) |
| AU (1) | AU2017235618B2 (enExample) |
| BR (1) | BR112018067602A2 (enExample) |
| CA (1) | CA3015432A1 (enExample) |
| CL (1) | CL2018002638A1 (enExample) |
| DK (1) | DK3429566T3 (enExample) |
| ES (2) | ES2856960T3 (enExample) |
| HK (1) | HK1259616A1 (enExample) |
| IL (1) | IL261457B (enExample) |
| MX (1) | MX374534B (enExample) |
| SG (1) | SG11201808009SA (enExample) |
| WO (1) | WO2017158199A1 (enExample) |
| ZA (1) | ZA201805562B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| US20230165856A1 (en) * | 2020-04-29 | 2023-06-01 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| JP2010535210A (ja) * | 2007-07-31 | 2010-11-18 | ギリード・コロラド・インコーポレーテッド | アンブリセンタンの代謝産物および誘導体 |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| KR20140130705A (ko) | 2012-02-29 | 2014-11-11 | 도레이 카부시키가이샤 | 체강액 저류 억제제 |
| WO2014138738A1 (en) * | 2013-03-08 | 2014-09-12 | Abbive Inc. | Methods of treating acute kidney injury |
| AU2014256944B2 (en) | 2013-04-26 | 2019-06-27 | La Jolla Pharma, Llc | Compositions and methods for treating renal failure |
| US20150125546A1 (en) * | 2013-11-06 | 2015-05-07 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
-
2016
- 2016-04-19 EP EP16166046.9A patent/EP3235496A1/en not_active Withdrawn
-
2017
- 2017-03-20 EP EP20175547.7A patent/EP3878439B1/en active Active
- 2017-03-20 CN CN201780017563.3A patent/CN109069443A/zh active Pending
- 2017-03-20 SG SG11201808009SA patent/SG11201808009SA/en unknown
- 2017-03-20 ES ES17711211T patent/ES2856960T3/es active Active
- 2017-03-20 BR BR112018067602A patent/BR112018067602A2/pt not_active Application Discontinuation
- 2017-03-20 DK DK17711211.7T patent/DK3429566T3/da active
- 2017-03-20 JP JP2019500021A patent/JP7237362B2/ja active Active
- 2017-03-20 HK HK19101803.4A patent/HK1259616A1/zh unknown
- 2017-03-20 KR KR1020187026495A patent/KR20180121539A/ko not_active Ceased
- 2017-03-20 MX MX2018011222A patent/MX374534B/es active IP Right Grant
- 2017-03-20 US US16/084,340 patent/US10870021B2/en active Active
- 2017-03-20 CA CA3015432A patent/CA3015432A1/en active Pending
- 2017-03-20 ES ES20175547T patent/ES2966638T3/es active Active
- 2017-03-20 EP EP17711211.7A patent/EP3429566B1/en active Active
- 2017-03-20 AU AU2017235618A patent/AU2017235618B2/en active Active
- 2017-03-20 WO PCT/EP2017/056476 patent/WO2017158199A1/en not_active Ceased
-
2018
- 2018-08-21 ZA ZA2018/05562A patent/ZA201805562B/en unknown
- 2018-08-29 IL IL261457A patent/IL261457B/en unknown
- 2018-09-14 CL CL2018002638A patent/CL2018002638A1/es unknown
-
2020
- 2020-10-07 US US17/065,097 patent/US11642307B2/en active Active
-
2023
- 2023-03-31 US US18/129,516 patent/US20230233454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230233454A1 (en) | 2023-07-27 |
| NZ746140A (en) | 2022-03-25 |
| IL261457A (en) | 2018-10-31 |
| DK3429566T3 (da) | 2021-03-29 |
| EP3878439A1 (en) | 2021-09-15 |
| EP3878439B1 (en) | 2023-10-04 |
| MX2018011222A (es) | 2019-01-10 |
| ES2966638T3 (es) | 2024-04-23 |
| ZA201805562B (en) | 2019-06-26 |
| JP2019515942A (ja) | 2019-06-13 |
| JP7237362B2 (ja) | 2023-03-13 |
| BR112018067602A2 (pt) | 2019-01-08 |
| US10870021B2 (en) | 2020-12-22 |
| CL2018002638A1 (es) | 2019-01-18 |
| AU2017235618B2 (en) | 2021-02-25 |
| WO2017158199A1 (en) | 2017-09-21 |
| EP3429566B1 (en) | 2021-01-27 |
| US11642307B2 (en) | 2023-05-09 |
| AU2017235618A1 (en) | 2018-09-27 |
| IL261457B (en) | 2021-09-30 |
| US20190083820A1 (en) | 2019-03-21 |
| CA3015432A1 (en) | 2017-09-21 |
| US20210046332A1 (en) | 2021-02-18 |
| EP3235496A1 (en) | 2017-10-25 |
| KR20180121539A (ko) | 2018-11-07 |
| HK1259616A1 (zh) | 2019-12-06 |
| MX374534B (es) | 2025-03-06 |
| SG11201808009SA (en) | 2018-10-30 |
| EP3429566A1 (en) | 2019-01-23 |
| CN109069443A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233454A1 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| RU2640023C2 (ru) | Жидкий состав | |
| Clark‐Price et al. | Physiology, pathophysiology, and anesthetic management of patients with renal disease | |
| JP2019142964A (ja) | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 | |
| AU2014346682B2 (en) | Novel formulations | |
| US20160296621A1 (en) | Formulations of bendamustine | |
| ES2906262T3 (es) | Composiciones para el tratamiento de la autodigestión | |
| Gross | Treatment of severe hyponatremia | |
| Reddi | Disorders of water balance: hyponatremia | |
| Cousins et al. | Anaesthesia, surgery and renal function: immediate and delayed effects | |
| NZ746140B2 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| US20210361600A1 (en) | Methods for inducing chondrogenesis | |
| NZ786075A (en) | Ambrisentan for use in the treatment of acute renal failure | |
| ES3014714T3 (en) | Use of ambrisentan for the treatment of portal hypertension | |
| EA013616B1 (ru) | Инъекционные препараты диклофенака и его фармацевтически приемлемых солей | |
| Agaba et al. | The renal concentrating mechanism and the clinical consequences of its loss | |
| D'Angio | Nonsteroidal antiinflammatory drug-induced renal dysfunction related to inhibition of renal prostaglandins | |
| JP2022518143A (ja) | ビタミンｅならびにがん治療用組成物および方法 | |
| RU2796724C1 (ru) | Многокомпонентный инфузионный раствор электролитов в комбинации с биологически активными компонентами для внутривенного введения | |
| Ichai et al. | Sodium disorders | |
| Kumar et al. | Therapeutic Suppression of mTOR Signaling Prevents and Reverses Salt-Induced Hypertension and Kidney Injury in Dahl Salt-Sensitive Rats | |
| Verbalis | The Posterior Pituitary 12 | |
| Skelly | Causes, consequences and control of potassium imbalances in small animals | |
| EP3955907A1 (en) | Pharmaceutical formulations containing p2y14 antagonists | |
| Proteinuria | Renal Transplant Dysfunction |